DAVID ANDREW BOCIAN
KESSLER TOPAZ MELTZER & CHECK LLP
- Address of record
- 280 KING OF PRUSSIA ROAD, RADNOR, PA 19087, 610-667-7706
- dbocian@ktmc.com
- Phone
- (610) 667-7706
Contact details as filed with the court in the cases below.
Case history
Publicly tracked matters where this attorney is listed as counsel.
Catalent Securities Settlement
Catalent, Inc. is facing a securities class action lawsuit brought by the City of Warwick Retirement System on behalf of investors. The settlement resolves claims related to publicly traded common stock and options that allegedly experienced price issues during the class period from August 30, 2021 through May 7, 2023.
- Claim deadline
- May 26, 2026
- Represents
- SEB INVESTMENT MANAGEMENT AB, PUBLIC EMPLOYEES RETIREMENT SYSTEM OF MISSISSIPPI
Mylan Securities Settlement
Mylan N.V. and certain executives are defendants in a securities class action alleging damages to investors. Defendants deny the claims and wrongdoing, but have agreed to settle for $60 million to eliminate the burden and expense of continued litigation. The settlement does not constitute an admission of wrongdoing by defendants.
- Settlement fund
- $60M
- Claim deadline
- July 10, 2026
- Represents
- PUBLIC EMPLOYEES' RETIREMENT SYSTEM OF MISSISSIPPI
Becton, Dickinson and Company Securities Litigation Settlement
Becton, Dickinson and Company and its former CEO Thomas E. Polen allegedly violated federal securities laws by misrepresenting the nature, extent, and revenue impact of undisclosed product issues, compliance violations, and FDA scrutiny regarding BD's Alaris infusion pump system during November 2019 to February 2020. The defendants have denied all wrongdoing while agreeing to settle for $85 million.
- Settlement fund
- $85M
- Claim deadline
- June 14, 2024
- Represents
- INDUSTRIENS PENSIONSFORSIKRING A/S
Celgene Corporation Securities Litigation Settlement
Celgene Corporation and certain of its officers violated federal securities laws by making false and misleading statements regarding pharmaceutical drugs and drug candidates, including GED-0301, Otezla, and Ozanimod during the class period. The defendants' misconduct allegedly damaged investors who purchased Celgene common stock.
- Settlement fund
- $239M
- Claim deadline
- April 13, 2026
- Represents
- AMF PENSIONSFORSAKRING AB
“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.